New safety information associated with the use of ZOLOFT(tm) in patients taking pimozide

05 марта, 2003
KIRKLAND, QC, March 5 /CNW/ - Pfizer Canada Inc. in consultation with Health Canada has informed Canadian health care professionals of clinically important new safety information concerning ZOLOFT capsules, a drug prescribed by physicians to relieve symptoms of depression, panic disorder or obsessive-compulsive disorder. Canada Newswire English via NewsEdge Corporation : KIRKLAND, QC, March 5 /CNW/ - Pfizer Canada Inc. in consultation with Health Canada has informed Canadian health care professionals of clinically important new safety information concerning ZOLOFT (sertraline hydrochloride) capsules, a drug prescribed by physicians to relieve symptoms of depression, panic disorder or obsessive-compulsive disorder. Based on the result of a recent clinical study, the concomitant use of ZOLOFT and pimozide (an anti-psychotic medication) is now contraindicated. Patients are advised not to take ZOLOFT with pimozide as their interaction may result in arrhythmias (irregular heartbeats), which may be serious and life- threatening. Patients should be aware that the symptoms of possible arrhythmia include dizziness, palpitations and fainting, and that they should seek immediate medical attention if these symptoms occur. If you are presently being treated with this drug combination, please consult your physician before changing your current therapy. This advisory is in addition to a letter issued to health care professionals reminding them of the above-mentioned safety information. As well, the product monograph for ZOLOFT is being revised to inform physicians regarding potential adverse effects this drug combination may cause. If patients have questions regarding their current prescription, they are asked to contact their physician or pharmacist. VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/cgi-bin/inquiry.cgi?OKEY=56403 -0- 03/05/2003 /For further information: please contact: Rhonda O'Gallagher, Senior Manager, Corporate Affairs, Pfizer Canada Inc., (514) 693-4090/ CO: ST: IN: SU: CNW 17:39e 05-MAR-03 <> << Copyright ©2003 Canada NewsWire >>
Разделы
Новости